Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 8

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 8
---
 repaid at closing, but are expected to be converted into shares of New Profusa Common Stock at a price of $2.22 per share. This compensation will not result in a material dilution of the equity interests of non -redeemingshareholders who hold the securities until the consummation of the de -SPACtransaction. See the section entitled “ Proposal No. 1 — The Business Combination Proposal — Interests of NorthView’s Directors, and Officers and Initial Stockholders in the Business Combination”. Conflicts of interest in connection with the Business Combination: The NorthView Initial Stockholders have potential conflicts of interest in recommending that stockholders vote in favor of approval of the Business Combination Proposal and approval of the other Proposals described in this proxy statement/prospectus. For instance, due to its ownership of founders shares that will become worthless if an initial business combination is not completed, the Sponsor will benefit from the completion of the Business Combination and may be incentivized to complete a business combination that is less favorable to shareholders rather than liquidating. Likewise, the Sponsor and its affiliates can earn a positive rate of return on their investments, even if the NorthView Public Holders experience a negative rate of return on their investments in NorthView and New Profusa. See the section entitled “ Proposal No. 1 — The Business Combination Proposal — Interests of NorthView’s Directors, and Officers and Initial Stockholders in the Business Combination”. for a further discussion of these considerations. The consolidated financial statements of appearing in this proxy statement/prospectus have been audited by Marcum LLP, independent registered public accounting firm. The headquarters of Marcum LLP are located at 730 3rd Ave 11th Floor, New York, NY 10017. NorthView’s securities were delisted from the Nasdaq Capital Market on December 27, 2024, due to our failure to complete an initial business combination within the timeframe required under Nasdaq Rule IM -5101-2 .NorthView’s shares of Common Stock, public warrants and rights are currently quoted on OTC Pink under the symbols “NVAC,” “NVACW,” and “NVACR” respectively. Upon consummation of the Business Combination, New Profusa’s shares of Common Stock and public warrants will be listed on the Nasdaq Capital Market under the symbols “PFSA” and “PFSAW,” respectively. NorthView’s units were issued in an initial public offering on December 22, 2021, and were subsequently separated on January 21